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Purpose: The Gleason score (GS) is an important factor that is considered when making 
decisions about prostate cancer and its prognosis. However, upgrading of the GS can 
occur between transrectal ultrasonography (TRUS) biopsy and radical prostatectomy. 
This study analyzed the clinical factors predictive of upgrading of the GS after radical 
prostatectomy compared with that at the time of TRUS biopsy.
Materials and Methods: We analyzed the medical records of 107 patients who had under-
gone radical prostatectomy. Patients were divided into two groups. Group 1 consisted 
of patients in whom the GS was not upgraded, and group 2 consisted of patients in whom 
the GS was upgraded. Associations between preoperative clinical factors and upgrading 
of the GS were analyzed. Preoperative clinical factors included age, prostate-specific 
antigen (PSA), prostate volume, PSA density, GS of TRUS biopsy, maximum core per-
centage of cancer, percentage of positive cores, number of biopsies, location of positive 
core with maximum GS, high-grade prostatic intraepithelial neplasia (HGPIN), in-
flammation on biopsy, and clinical stage.
Results: Among 85 patients, 42 (49%) patients had an upgraded GS after operation. 
TRUS biopsy core number of 12 or fewer (p=0.029) and prostate volume of 36.5 ml or 
less (p＜0.001) were associated with upgrading of the GS. Preoperative clinical factors 
associated with nonupgrading of the GS were the detection of positive cores with a max-
imum GS at the apex (p=0.002) or in a hypoechoic lesion (p=0.002) in TRUS.
Conclusions: If the positive cores with maximum GS are located at the apex or in a hypo-
echoic lesion in TRUS, we can expect that the GS will not be upgraded. In patients with 
the clinical predictive factors of a prostate volume of 36.5 ml or less and TRUS biopsy 
core number of less than 12, we can expect upgrading of the GS after radical prostatec-
tomy, and more aggressive treatment may be needed.
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After the introduction of prostate-specific antigen (PSA) as 
a screening test for prostate cancer, the number of patients 
diagnosed as having prostate cancer and the proportion of 
low-risk prostate cancer have increased [1]. A diagnosis of 
prostate cancer is confirmed by transrectal ultrasono-
graphy (TRUS) biopsy. The biopsy result includes the 
Gleason score, which indicates the tumor grade. The 
Gleason score, which is a combination of PSA, prostate size, 
and clinical stage, represents the aggressiveness of the 
prostate cancer and is an important clinical factor that is 
considered when making decisions about treating prostate 
cancer and its prognosis [2]. 
　However, according to recent studies of TRUS biopsy, 
pathological upgrading of the Gleason score can occur be-
tween the pathologic reports of the TRUS biopsy specimen 
and the radical prostatectomy specimen. The discordance 
rate of the Gleason score from TRUS biopsy and radical 
prostatectomy is known to range from 24% to 50% [3-7]. Korean J Urol 2010;51:677-682
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Various preoperative clinical factors reported to be asso-
ciated with upgrading of the Gleason score are PSA, pros-
tate volume, number of biopsy cores taken, number of pos-
itive cores, and inter- and intra-observer variation [8,9]. 
　Clinically insignificant cancer is defined as cancer with 
a tumor volume ＜0.2 cm
3, a Gleason score ≤6 from TRUS 
biopsy, and pathologic stage of T2c or less. Predictive fac-
tors for this cancer are a clinical stage of T1c, absence of 
Gleason grade 4 or 5 on TRUS biopsy, PSA density less than 
0.15 ng/ml/cm
3, cancer detected at less than 3 cores, and 
core density less than 50%. 
　Watchful waiting or active surveillance can be consid-
ered as one of the treatment modalities in patients matched 
to these criteria [10]. However, in cases of prostate cancer 
with a Gleason grade ≥4 or score (or sum) ≥7, watchful 
waiting or active surveillance is not appropriate because 
of the poor prognosis of this cancer [11] and the higher rate 
of capsular invasion or biochemical recurrence [12]. Thus, 
the Gleason score is associated with the aggressiveness 
and prognosis of prostate cancer [13]. Therefore, accurate 
grading is crucial in deciding treatment modalities for 
prostate cancer such as radical prostatectomy, radiation 
therapy, or active surveillance [11,14]. 
　According to D’Amico et al, patients with stage T1c, T2a, 
PSA level ≤10 ng/ml and Gleason score ≤6 are low-risk 
prostate cancer and these patients has low risk for death 
[12]. Therefore it is alleged that radical prostatectomy to 
low risk patients is overtreatment. However, the dis-
cordance rate in the Gleason score from TRUS biopsy and 
that from radical prostatectomy is known to be up to 50%. 
Therefore, even though a patient is diagnosed as having 
low-risk prostate cancer after TRUS biopsy, preoperative 
clinical factors predictive of Gleason score upgrading 
should be considered when treating prostate cancer. 
　The aim of this study was to identify the factors pre-
dictive of upgrading of the Gleason score, which can change 
the treatment modality combined with PSA, prostate vol-
ume, and clinical stage, and to identify a means of more ac-
curately diagnosing the Gleason score by TRUS biopsy.
MATERIALS AND METHODS
We retrospectively analyzed the medical records of 107 pa-
tients who had undergone radical prostatectomy under a 
diagnosis of prostate cancer from January 2000 to February 
2010. Every patient was diagnosed with prostate cancer by 
TRUS biopsy. TRUS biopsies were performed in patients 
with elevated serum PSA, abnormal digital rectal exami-
nation findings, and the presence of a hypoechoic lesion on 
TRUS. TRUS biopsy was performed with the ultrasound 
machine SA-8000 Ex Prime (Medison, Seoul, Korea). The 
number of biopsy cores taken ranged from 6 to 12 and an 
additional target biopsy was performed if needed. Biopsy 
slides were deciphered by a pathologist at our institute ap-
plying the 2005 International Society of Urological Patho-
logy (ISUP) consensus. Biopsy slides of other institutes 
were deciphered by the pathologist of our institute again 
to confirm the diagnosis of prostate cancer and Gleason 
score. Biopsy results included the number of cores taken, 
length of biopsy core, Gleason score of positive cores, loca-
tion of positive cores, and tumor length in positive cores. The 
2002 TNM staging system of the American Joint Commit-
tee on Cancer (AJCC) was used for clinical staging. Serum 
PSA was measured before TRUS biopsy. Patients who re-
ceived androgen deprivation therapy or radiation therapy, 
those diagnosed by transurethral resection of the prostate 
before radical prostatectomy, and those who did not have 
a sufficient TRUS biopsy result were excluded.
　Open retropubic radical prostatectomy or robot-assisted 
radical prostatectomy was performed in all patients with 
localized and locally advanced prostate cancer. The radical 
prostatectomy specimen was sliced into 3 mm serial sec-
tions and deciphered by applying the same method of biop-
sy and by 2 pathologists when the result was conflicting. 
　The maximum Gleason scores in the TRUS biopsy and 
radical prostatectomy specimens were compared. Upgrading 
of Gleason score was defined as an elevation of the Gleason 
score after radical prostatectomy compared with TRUS 
biopsy. Patients were divided into two groups. Group 1 
comprised patients in whom the Gleason score was not up-
graded, and group 2 comprised patients in whom the 
Gleason score was upgraded after radical prostatectomy. 
We analyzed the data for any associative factors between 
upgrading of the Gleason score and preoperative para-
meters. Preoperative parameters included age, PSA, pros-
tate volume, PSA density, number of biopsy cores taken, 
maximum core percentage, Gleason score of TRUS biopsy, 
location of the positive core with the maximum Gleason 
score, percentage of positive cores, high-grade prostatic in-
traepithelial neplasia (HGPIN), inflammation on biopsy, 
and clinical stage.
　Statistical analysis was performed by use of Student’s 
t-test for continuous variables and the Pearson chi-square 
test and Fisher exact test for categorical variables. The 
software used for statistical analysis was SPSS ver. 12.0 
(SPSS Inc., Chicago, IL, USA), and a p-value of less than 
0.05 was considered to be statistically significant.
RESULTS
The medical records of a total of 107 patients were re-
viewed; 22 patients were excluded because of neoadjuvant 
hormonal therapy, diagnosis by TURP, or not enough 
TRUS biopsy information. A total of 50 patients underwent 
open retropubic prostatectomy and 35 patients underwent 
robot-assisted radical prostatectomy. The mean age of the 
patients who underwent radical prostatectomy was 64.7± 
7.0 years, their mean PSA was 8.83±7.46 ng/ml, their mean 
TRUS volume was 40.2±10.2 ml, and their mean PSA den-
sity was 0.23±0.20 ng/ml/cm
3 (Table 1). Among 85 patients, 
45 (53%) had a Gleason score of 6 (3＋3), 23 (27%) had a 
Gleason score of 7 (3＋4), 10 (12%) had a Gleason score of 
7 (4＋3), 5 (6%) had a Gleason score of 8 (4＋4), and 2 (2%) 
had a Gleason score of 9 (5＋4) (Table 2). The distribution Korean J Urol 2010;51:677-682
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Age (yr) 64.7±7.0  64.0±7.1  65.4±6.9  0.367
b
PSA (ng/ml) 8.83±7.46 8.73±6.71 8.94±8.26 0.897
b
PSA density (ng/ml/cm
3) 0.23±0.20 0.21±0.17 0.26±0.24 0.253
b
Prostate volume (ml) 40.2±10.2 43.4±9.9  36.8±9.5  0.002
b
Preoperative clinical stage
2a 39 (46) 21 (49) 18 (43)
0.760
c 2b 14 (17) 8 (19) 6 (14)
2c 24 (28) 10 (23) 14 (33)
3a 8 (19) 4 (10) 4 (10)
PSA: prostate-specific antigen, 
a: Group 1 - Gleason score not upgraded after radical prostatectomy; Group 2 - Gleason score upgraded
after radical prostatectomy, 
b: Student's t-test; Mean±SD, 
c: chi-square test; n (%)











GS6 (3＋3) 45 (53) 21 (49) to GS7 (3＋4) 13 (31)
0.259
b
to GS7 (4＋3) 9 (21)
to GS9 (4＋5) 2 (5)
GS7 (3＋4) 23 (27) 10 (23) to GS7 (4＋3) 9 (21)
to GS8 (4＋4) 4 (10)
GS7 (4＋3) 10 (12) 6 (14) to GS8 (4＋4) 2 (5)
to GS9 (4＋5) 2 (5)
GS8 (4＋4) 5 (6) 4 (9) to GS9 (4＋5) 1 (2)
GS9 (5＋4) 2 (2) 2 (5) 0 0 (0)
TRUS: transrectal ultrasonography, GS: Gleason score, 
a: Group 1 - Gleason score not upgraded after radical prostatectomy; Group
2 - Gleason score upgraded after radical prostatectomy, 
b: chi-square test; n (%)
of clinical T stage was 39 (46%) at cT2a, 14 (17%) at cT2b, 
24 (28%) at cT2c, and 8 (19%) at cT3 (Table 1).
　The Gleason score was upgraded in 42 (50%) patients af-
ter radical prostatectomy. Among the patients with an up-
graded Gleason score, 13 patients had their Gleason score 
upgraded from a Gleason score of 6 (3＋3) to a Gleason score 
of 7 (3＋4), 9 patients from a 6 to a Gleason score of 7 (4＋3), 
and 2 patients from a 6 to a Gleason score of 9 (4＋5). Nine 
patients had their Gleason score upgraded from a Gleason 
score of 7 (3＋4) to a Gleason score of 7 (4＋3), and 4 patients 
from a 7 to a Gleason score of 8 (4＋4). Two patients had 
their score upgraded from a Gleason score of 7 (4＋3) to a 
Gleason score of 8 (4＋4), and 2 patients from a 7 to a Gleason 
score of 9 (4＋5). Lastly, the score in 1 patient was upgraded 
from a Gleason score of 8 (4＋4) to a Gleason score of 9 (4＋5) 
(Table 2).
　There were no statistically significant differences in age, 
PSA, or PSA density between the two groups. However, 
prostate volume was significantly smaller in group 2 (43.4 
ml vs. 36.8 ml, p=0.002) (Table 1).
　The cutoff value for prostate volume that was a pre-
dictive parameter for upgrading of Gleason score by 
Student’s t-test was calculated by receiver operating curve 
(ROC). A prostate volume of less than 36.5 ml was shown 
to be a predictive parameter for upgrading of the Gleason 
score. Sensitivity was 0.744 and specificity was 0.690 (area 
under curve (AUC): 00.720, p＜0.001, 95% confidence in-
terval: 0.610-0.829). 
　Among 85 patients, 1 patient did not have information 
about the number of biopsy cores. In the remaining 84 patients, 
biopsy cores numbering 13 or more showed statistical sig-
nificance for nonupgrading (p=0.029). Gleason score, maxi-
mum core percentage, percentage of positive cores, clinical 
stage, HGPIN, and inflammation on biopsy were not stat-
istically significant for upgrading (Tables 2, 3). 
　TRUS biopsy was performed in all patients at the apex, 
mid, and base, but not at the other cores. Our results show 
that the location of positive cores with a maximal Gleason 
score at the apex (p=0.002) or obtained through target biop-
sy on a hypoechoic lesion (p=0.002) were statistically sig-
nificant for nonupgrading (Table 4). Korean J Urol 2010;51:677-682
680 Moon et al
TABLE 3. Comparison of TRUS biopsy factors between group 1 and group 2








No. of total biopsy cores 11.0±1.8 11.3±1.7 10.8±1.9 0.55
c
Maximum core percentage (%) 28.8±19.7 29.1±20.5 28.5±19.1 0.883
b
Percentage of positive cores (%) 29.7±22.7 28.0±22.3 29.7±21 0.709
b
Prostate intraepithelial neoplasia (HGPIN)
　Negative 76 (89) 39 (91) 37 (88)
0.738
d
　Positive 9 (11) 4 (9) 5 (12)
Inflammation
　Negative 67 (79) 35 (81) 32 (76)
0.557
c
　Positive 18 (21) 8 (19) 10 (24)
No. of total biopsy cores 84 42 42
　≤12 75 (89) 34 (81) 41 (98)
0.029
d
　≥13 9 (11) 8 (19) 1 (2)
　7 2 (2) 0 (0) 2 (5)
　8 13 (15) 6 (14) 7 (17)
　9 2 (2) 0 (0) 2 (5)
　10 12 (14) 8 (19) 4 (10)
　11 2 (2) 1 (2) 1 (2)
　12 44 (52) 19 (45) 25 (60)
　13 6 (7) 6 (14) 0 (0)
　14 2 (2) 2 (5) 0 (0)
　15 1 (1) 0 (0) 1 (2)
TRUS: transrectal ultrasonography, In Group 1: one patient did not have information about the number of biopsy cores, 
a: Group 1
- Gleason score not upgraded after radical prostatectomy; Group 2 - Gleason score upgraded after radical prostatectomy, 
b: Student's 
t-test; Mean±SD, 
c: chi-square test; n (%), 
d: Fisher exact test; n (%)
TABLE 4. Comparison of location of positive cores with maximum
Gleason score between group 1 and group 2









　Negative 15 (35) 29 (69)
0.002
c
　Positive 28 (65) 13 (31)
Mid 
　Negative 21 (49) 18 (43)
0.369
c
　Positive 22 (51) 24 (57)
Base
　Negative 20 (47) 12 (29)
0.069
c
　Positive 23 (53) 30 (71)
Central
b
　Negative 17 (53) 23 (62)
0.304
c
　Positive 15 (47) 14 (38)
Hypoechoic lesion
b
　Negative 0 (0) 4 (67)
0.002
d
　Positive 16 (100) 2 (33)
TRUS: transrectal ultrasonography, 
a: Group 1 - Gleason score not
upgraded after radical prostatectomy; Group 2 - Gleason score up-
graded after radical prostatectomy, 
b: not all patients had TRUS
biopsy samples taken at these cores; data were collected in pa-
tients who had biopsy results for these cores, 
c: chi-square test; n
(%), 
d: Fisher exact test; n (%)
DISCUSSION
Gleason score, PSA, clinical stage, and prostate volume are 
crucial parameters to be considered when treating prostate 
cancer. The Gleason score is the most reliable factor in de-
termining the biological characteristics of prostate cancer, 
tumor stage, and its prognosis. Therefore, accurate diag-
nosing of the Gleason score is very important for choosing 
proper treatment modalities in prostate cancer [14].
　Recent studies have focused on the discordance in Gleason 
score between TRUS biopsy and radical prostatectomy 
specimens; discordance is reported to range from 24% to 
50% [4-7]. Several factors including PSA level, prostate vol-
ume, size of the tumor mass, preoperative clinical stage, 
and inter- and intra-observer variation are known to be as-
sociated with upgrading of the Gleason score between 
TRUS biopsy and radical prostatectomy [1,15]. 
　Nayyar et al reported that upgrading of the Gleason 
score is not associated with a high PSA level [16]. Unlike 
the report from Nayyar et al, Dong et al reported that 55% 
of patients were upgraded from a Gleason score of 6 to a 
Gleason score of 7 or higher and that a PSA level greater 
than 5.0 ng/ml is associated with upgrading of the Gleason 
score [7]. Freedland et al and Tilki et al also reported that 
a high PSA level is associated with upgrading of the 
Gleason score [9,17]. In our study, however, we did not de-
termine the PSA level to be a predictive parameter of 
upgrading. Korean J Urol 2010;51:677-682
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　Moussa et al reported that smaller prostate volume is as-
sociated with upgrading of the Gleason score [14]. 
Furthermore, Turley et al reported that patients with a 
TRUS volume of 20 cm
3 or less had more than five times 
the risk of upgrading compared with patients with a TRUS 
volume of more than 60 cm
3 [18]. In our study, patients with 
a TRUS volume of 36.5 ml or less had a relatively higher 
risk of upgrading of the Gleason score after radical 
prostatectomy. Associations between smaller prostate vol-
ume and upgrading of the Gleason score can be explained 
by several theories. Kassouf et al reported that PSA ele-
vation induced by hyperplasia in large prostates leads to 
earlier TRUS biopsy and this enables the detection of early 
prostate cancer with a well-differentiated component [19]. 
Turley et al reported that prostate cancer arising in small 
prostates is more biologically aggressive and is associated 
with a higher pathologic grade of tumor [18]. 
　In our study, 53% of patients diagnosed as having a 
Gleason score of 6 by TRUS biopsy had an upgraded 
Gleason score after radical prostatectomy. This result im-
plies that nearly half of the patients diagnosed as having 
a Gleason score of 6 by TRUS biopsy had more aggressive 
cancer than they seemed to have. If the actual Gleason 
score is 7 in patients who are undergoing radiation therapy 
under the diagnosis of prostate cancer with a Gleason score 
of 6, this difference could tremendously influence the treat-
ment strategy. Therefore, even if patients are diagnosed 
with low-risk prostate cancer after TRUS biopsy, physi-
cians should always consider parameters that can be pre-
dictive of upgrading to high-risk prostate cancer. 
　Kahl et al reported that an extended biopsy scheme with 
cores numbering more than 12 can help to acquire more ac-
curate Gleason scores than a biopsy scheme with cores 
numbering less than 12 [20]. This report shows similar out-
comes with previous reports stating that an extended biop-
sy scheme can improve the concordance of the Gleason 
score [21,22]. In this study, cores numbering from 7 to 11 
were composed of 6 routine biopsy cores and additional tar-
get biopsies on hypoechoic lesions. Cores numbering from 
13 to 15 were composed of 12 routine biopsy cores and addi-
tional target biopsies on hypoechoic lesions. In the 6-core 
biopsy scheme, there was a high rate of upgrading despite 
target biopsy. In the 12-core biopsy scheme, however, there 
was a remarkable decrease in the rate of upgrading of the 
Gleason score with target biopsy. Therefore, biopsy cores 
numbering more than 13 composed of the 12 routine biopsy 
cores and additional target biopsy should be taken for accu-
rate grading of the Gleason score. This conclusion was sup-
ported with statistical significance (p=0.029). 
　Most prostate cancer arises from the peripheral zone. 
Tumor frequency is reported to be 85.5% at midgland and 
82.3% at the apex. Also, prostate cancers are significantly 
denser in the apex to midgland, particularly in the anterior 
half of the gland [23]. However, the correlation between up-
grading or downgrading of the Gleason score and the loca-
tions of cores taken during TRUS biopsy has not yet been 
clearly defined. In this study, there was statistical sig-
nificance in nonupgrading between the maximum Gleason 
score of cores taken at the apex and obtained through target 
biopsy on hypoechoic lesions and that of radical prostatec-
tomy (p=0.002 and p=0.002). Giving consideration to the 
facts of a higher tumor density at the apex, denser tumor 
cells at hypoechoic lesions on TRUS, and the results of our 
study, physicians can acquire more accurate information 
on Gleason score preoperatively through target biopsy of 
hypoechoic lesions and biopsy at the apex.
　The results of the present study suggest that at least 13 
cores should be taken during TRUS biopsy and more ag-
gressive biopsy should be performed at the apex and of hy-
poechoic lesions for more precise Gleason score pre-
operatively. In cases of a prostate volume of 36.5 mg or less, 
upgrading of the Gleason score can be predicted and more 
aggressive treatment may be needed. 
　There are several limitations to the present study. First, 
this study was conducted retrospectively at a single in-
stitute and the study population was relatively small. 
Second, this study did not identify the relation between up-
grading and factors such as the PSA doubling time, free 
PSA, and Gleason score ＜6 after TRUS biopsy. Third, be-
cause the biopsy strategy was not consistent, the biopsy 
specimens were not taken at exactly the same location in 
every patient. However, our study excluded patients tak-
ing neoadjuvant hormonal therapy and radiation therapy 
and provides comprehensive information on both localized 
and locally advanced prostate cancer, as well as the correla-
tions between the locations of cores taken during TRUS bi-
opsy and upgrading of the Gleason score. Further large- 
scale, prospective, multi-center studies are needed to con-
firm the correlations between preoperative parameters 
and upgrading of the Gleason score. 
CONCLUSIONS
Among patients who had undergone radical prostatectomy 
after a diagnosis of prostate cancer, the Gleason score was 
upgraded in 50% of patients after radical prostatectomy. 
Non-upgrading could be predicted in patients with more 
than 13 TRUS biopsy cores and when the maximum 
Gleason score was detected at the apex or in a hypoechoic 
lesion. In cases of a prostate volume of 36.5 mg or less or 
a Gleason score of 6, upgrading of the Gleason score can be 
predicted and more aggressive treatment may be needed.
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